Artiva Biotherapeutics, Inc. (ARTV) stock
ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.86−0.10 (-2.53%)
Close on Nov 17, 2026Market cap $188.72MP/E –Yield –
Artiva Biotherapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Artiva Biotherapeutics's profit margin for the twelve months ending Dec 31, 2024 was -26045.0%. For fiscal 2024 it was -26045.0%, against -85.8% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -26045.0% | −25959.3 |
| FY2023 | Dec 31, 2023 | -85.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2024 | Mar 31, 2024 | -5562.9% | – |
| Q4 FY2023 | Dec 31, 2023 | -510.6% | – |
| Q3 FY2023 | Sep 30, 2023 | 42.3% | – |
| Q2 FY2023 | Jun 30, 2023 | -322.7% | – |
See a number that looks wrong?